Olin Corporation

▲ Bull Case

• ◆ECU netback recovery to $420+ by 2029 drives CAPV EBITDA from $400M (2026E) to $775M (2030E)—a $375M EBITDA tailwind from Chinese alumina demand recovery, US PVC/housing improvement, and continued capacity discipline from US producers
• ◆Beyond250 structural cost program delivers $200–325M cumulatively by 2028, raising EBITDA floor independent of commodity recovery and demonstrating Olin can compete on cost not just cycle timing
• ◆Winchester emerges as a $3.5–4.5B standalone asset—military mix growing 8–15% CAGR on DoD stockpile rebuilding, with brand and qualification barriers commanding 9–10x EBITDA vs. chemicals multiples currently applied

▼ Bear Case

• ◆Chinese chlor-alkali overcapacity persists, with caustic soda exports keeping prices below $300/ton through 2028—locking ECU netbacks below $300 and capping CAPV EBITDA at $400–450M annually
• ◆Balance sheet stress at peak leverage 5.0–5.4x in 2025–2026 forces dividend cut, halts buybacks, and risks credit downgrade to high-yield, eliminating the per-share accretion pillar of the thesis
• ◆Beyond250 underdelivers ($75–125M vs. $250M target), Epoxy losses persist, and Winchester military contracts grow slowly (3–5%) as Ukraine support winds down—EBITDA reaches only $850M by 2030 vs. $1.15B base case

“The Street's consensus rating is Hold with median 1-year price target of $23—implying ~15% downside from current $27.05. The debate has four axes: (1) Cycle timing—bulls model 2026–2027 ECU recovery; bears push to 2028–2029. (2) Leverage trajectory—will Olin breach covenants if EBITDA stays below $700M in 2026? Most analysts say no but flag the risk. (3) Beyond250 credibility—how much of management's $250M target will actually flow through? Consensus assumes 50–60% delivery. (4) Strategic optionality (Epoxy divestiture, Winchester separation)—largely not priced in by Street models. Our differentiated take: Q4 2025 Freeport miss is operational (Ken Lane's reliability challenge) not structural. Chlor-alkali fundamentals are intact. Our 2026 EBITDA of $610M is 21% above consensus. We assume 75–85% Beyond250 delivery, peer-aligned. Sachem Head's catalytic potential for Epoxy divestiture is real and underpriced.”

• ◆Q1/Q2 2026 EBITDA beats vs. depressed Q4 2025 anchor—recovery confirmation
• ◆Caustic soda contract pricing >$340/dry ton sustained 6+ months—leading indicator of ECU recovery
• ◆Beyond250 program update at Q3 2026 earnings—credibility check on $50–70M annualized savings
• ◆Chinese chlor-alkali policy shift (capacity rationalization, export restrictions)—most underappreciated upside
• ◆Epoxy divestiture or strategic announcement—eliminates EBITDA drag, reduces leverage
• ◆Winchester strategic action (spinoff, sale, IPO of standalone)—30–50% one-day catalyst potential
• ◆DoD ammunition procurement acceleration—military stockpile rebuilding from Ukraine drawdown

• ◆ECU netback structural impairment below $250/ECU sustained 2+ years—CAPV near-breakeven, EBITDA collapses to $350M, dividend cut
• ◆Balance sheet/covenant breach—net debt above $3.5B with EBITDA below $700M pushes leverage past 5x; covenant pressure forces dividend cut + asset sale
• ◆Freeport operational reliability—repeated unplanned outages signal aging infrastructure requiring step-change capex
• ◆Winchester secular decline—civilian ammunition channel surplus persists; lead restrictions; competitive pressure
• ◆Epoxy losses persist through 2027—$60–80M annual drag with no buyer
• ◆Chinese caustic export acceleration—Chinese overcapacity dumps global pricing
• ◆DoD contract loss—low probability but high impact; eliminates military growth pillar
• ◆Sachem Head exits—loss of activist anchor; 21.5% block creates selling pressure